Skip to main content
Equibles
ZIVO logo

ZIVO · Zivo Bioscience, Inc. · Metrics

Track ZIVO — free

Use ZIVO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ZIVO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.67 At close · Nov 27
Rebalance outlook locked
Going-concern doubt — flagged Nov 14, 2025

Substantial doubt about the company's ability to continue as a going concern.

“These factors raise substantial doubt about the Company's ability to continue as a going concern within one year after the date the financial statements are issued.”
View the 10-Q filed Nov 14, 2025
Market Cap
$16.53M
Shares
3.89M
Volume · Nov 27 226.8K Avg daily vol (21 sessions) 42.21K

ZIVO metrics

43 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.67
Market cap
$16.53M

Price action

20 metrics
Price change (1W)
-43.7%
Price change (30D)
—
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
—
Annualized volatility (3M)
—
Beta
—
RSI (14D)
5.5
Price vs SMA 50
—
Price vs SMA 200
—
Avg volume (3M)
42,210
Relative volume
5.4
Average dollar volume
$54,094

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
3.89M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
79.1×
reciprocal yield 1.3%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-51.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
31.7%
Operating margin
-4,045.7%
Trailing 12 months
Net margin
-4,059.7%
Gross profit (TTM)
$66,210
Operating profit (TTM)
−$8.46M
Net income (TTM)
−$8.49M
Trailing 12 months
Diluted EPS (TTM)
$-2.13
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.06
Gross profit per diluted share (TTM)
$0.02
Operating profit per diluted share (TTM)
$-2.27
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-2.28
Operating cash flow per diluted share (TTM)
$-0.83
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$0.99
Stock compensation per diluted share (TTM)
—
Book value per share
$-0.14

Growth

11 metrics
Revenue growth YoY
+108.3%
Year over year
Net income growth YoY
—
Revenue (TTM)
$209,025
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+11.9%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-1,516.8%
Debt / equity
—
Current ratio
0.1
EBITDA (TTM)
−$8.95M
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$57,222
Total assets
$559,452
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$3.08M
Capital expenditures (TTM)
—
R&D (TTM)
$3.70M
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
1,768.1%
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
1
13F filer change QoQ
-1
Institutional ownership
0.1%
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-2.3%
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1101026 CUSIP 98978N309 13F (30d) 1 filings 1 filers Visit website Investor relations